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A PEDIATRIC CASE OF TREATMENT-RELATED MYELODYSPLASTIC
SYNDROME WHILE ON THERAPY FOR PRE-B ALL
Sara McElroy, MD; G Douglas Myers, MD; Terrie Flatt, DO
Children’s Mercy Kansas City

Introduction
• Secondary malignancies, including therapy-related myelodysplastic
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• This patient developed t-MDS while receiving therapy for pre-B ALL, 2 years after his
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initial dose of cyclophosphamide.

syndrome (t-MDS) and acute myeloid leukemia (AML), are an uncommon
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late effect of cancer therapy.
• When t-MDS/AML occurs after treatment with alkylating agents, it is

• Adult and pediatric studies have shown that treatment with hypomethylating agents

• Average time to development of t-MDS/AML after alkylating agents is
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• Hypomethylating agents prolong overall survival and are approved for use

relapse at 20 months post-transplant.

studies demonstrating 5-year survival rates <25%.

• Adult data suggests that maintenance therapy after transplant with hypomethylating

Case Description

• The patient received the standard high-risk arm of AALL1131 and a total
dose of 3000 mg/m2 cyclophosphamide.
• During cycle 6 of maintenance therapy, a routine CBC had 2.8% blasts.
• A bone marrow aspirate (see Images) demonstrated severe erythroid and
megakaryopoietic dyspoiesis with 13% myeloblasts by flow cytometry.
There was no abnormal immature B-cell population.
• Chromosome analysis showed a reciprocal t(3;3)(q21.3;q26.2); GATA2,
MECOM translocation with monosomy 7, consistent with a diagnosis of
t-MDS.

was demonstrated in this case, with the patient’s blast percentage decreasing from
• Patients with t-MDS/AML are at high risk of post-transplant relapse and >70% will

• The prognosis of t-MDS/AML is very poor despite stem cell transplant with

negative MRD by flow cytometry at the end of induction.

prior to transplant can reduce blast percentages and decrease risk of relapse. This

13% at diagnosis to 2% after 4 cycles of azacitidine.

in adults with myeloid malignancies.

risk pre-B ALL (CNS2) and received a standard 4-drug induction with

after treatment with cyclophosphamide and monosomy 7 cytogenetics.

which may have been a factor in the early development of disease.

inhibitors which is associated with 11q23 translocations.

• The patient is a 17-year-old Hispanic male who was diagnosed with high

• This case demonstrates a much more rapid development of t-MDS than is expected
• Hispanics have a higher incidence of t-MDS/AML compared to other racial groups

associated with monosomy 5 and/or 7, in contrast to after topoisomerase 2

typically 5 to 7 years after receiving therapy.

Discussion

agents reduce early relapse, but there is little to no data in pediatrics. This patient

Clinical Course

remains in remission 10 months post-transplant.

Conclusions

• The patient completed 4 cycles of azacitidine (hypomethylating agent), prior to
transplant. The peripheral blast count cleared after completion of all 4 cycles
of azacitidine and the blast percentage in his marrow decreased to 2%.
• Fludarabine, busulfan, melphalan, and rabbit ATG were given as myeloablative
conditioning for haplo-identical allogeneic bone marrow transplant.
• The patient received a CD34-selected, T-cell-depleted transplant. On Day +30
his marrow was negative for disease by flow cytometry and cytogenetics.
• On day +60 post-transplant we initiated decitabine maintenance therapy to
prevent relapse. The patient completed 6 cycles of decitabine. Follow-up
marrow evaluations after 2, 4, and 6 cycles have demonstrated no evidence of
myelodysplasia or leukemia.

The authors thank Dr. Weijie Li for providing pathology images
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• Alkylating agents are a known cause of t-MDS/AML. This case demonstrates a rare
instance of t-MDS developing on-therapy.
• Hypomethylating agents should be considered in patients with t-MDS prior to
transplant, to limit additional chemotherapy in already heavily-treated patients.
• Maintenance therapy with hypomethylating agents post-transplant should be
considered in patients at high risk of relapse.
• Further studies are needed among pediatric patients to validate the use of
maintenance therapy with hypomethylating agents post-transplant to decrease the
risk of relapse.

